Drug intelligence / Profile preview

sonrotoclax + dexamethasone + carfilzomib

Development stage: Unknown
Lead developer: BeOne Medicines
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Fragment-Derived Small Molecules → Multivalent & Scaffold-Based Small Molecules → Small Molecules
Administration: Oral (sonrotoclax, Dexamethasone), Intravenous (carfilzomib)

Overview

A combination regimen consisting of **sonrotoclax** (BGB-11417), **dexamethasone**, and **carfilzomib** is currently being investigated primarily for the treatment of relapsed/refractory multiple myeloma (RRMM) in patients harboring t(11;14)[5]. - **Sonrotoclax** is a next-generation small molecule inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (BCL2), designed to be more potent, selective, and to overcome resistance seen with earlier BCL2 inhibitors[1][5]. - **Dexamethasone** is a synthetic glucocorticoid corticosteroid with anti-inflammatory and antineoplastic properties. - **Carfilzomib** is a small molecule proteasome inhibitor, used in combination with dexamethasone and other agents in multiple myeloma for its cytotoxic effects on malignant plasma cells. The combination aims to synergistically induce apoptosis via BCL2 inhibition, enhance cytotoxicity through proteasome inhibition, and increase antitumoral activity with corticosteroid support. The triple combination is under clinical investigation for dose finding, safety, and efficacy in relapsed/refractory multiple myeloma populations, and development is ongoing at Phase 1b/2 as of 2025[5].

Brand names: No registered brand names for the combination
Other names: sonrotoclax + dexamethasone + carfilzomib

Targets

BCL-2 (BCL-2 family)GR (Glucocorticoid receptor)PSMB5 (Proteasome subunit beta Type-5)

Beyond the preview

Go deeper on sonrotoclax + dexamethasone + carfilzomib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sonrotoclax + dexamethasone + carfilzomib.

Explore the full profile